logo.jpg
IntelGenx Announces Closing of First Tranche of Non-Brokered Private Placement From Strategic Partner for Approximate Aggregate Gross Proceeds of US$3 Million (Including US$750,000 to be Received by the Company Once Shareholder Approvals Have Been Obtained)
August 31, 2023 08:30 ET | IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Aug. 31, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) announces the closing of the first tranche of a...
logo.jpg
IntelGenx Reports Second Quarter 2023 Financial Results
August 14, 2023 16:03 ET | IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Aug. 14, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the second quarter...
logo.jpg
IntelGenx Announces First Agreement for CDMO Packaging Services
August 10, 2023 16:30 ET | IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Aug. 10, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has entered into a binding term sheet agreement...
logo.jpg
IntelGenx to Report Second Quarter 2023 Financial Results on August 14, 2023 – Conference Call to Follow
August 07, 2023 16:30 ET | IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Aug. 07, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its...
logo.jpg
IntelGenx Completes Enrollment for ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease
August 01, 2023 08:00 ET | IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Aug. 01, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has completed patient enrollment in the ongoing...
logo.jpg
IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Parkinson’s Disease
July 25, 2023 08:00 ET | IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, July 25, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the execution of a Research Grant Agreement with...
logo.jpg
IntelGenx Announces a Change to its Board of Directors
July 21, 2023 16:30 ET | IntelGenx Technologies Corp.
SAINT-LAURENT, Quebec, July 21, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces the resignation of Mr. J. Bernard (Bernie)...
logo.jpg
IntelGenx Announces Voting Results on Election of Directors
July 06, 2023 16:30 ET | IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, July 06, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces that, at the annual meeting of shareholders of...
logo.jpg
IntelGenx Unveils Short-Term Commercial Objectives
May 31, 2023 08:00 ET | IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, May 31, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it is executing on a plan focussed on near-term...
logo.jpg
IntelGenx Receives Amended DEL License to Conduct Third-Party Testing
May 17, 2023 08:00 ET | IntelGenx Technologies Corp.
- Provides opportunity to address market gap, catering to growing industry demand for reliable and efficient testing services - SAINT LAURENT, Quebec, May 17, 2023 (GLOBE NEWSWIRE) -- IntelGenx...